Omidenepag Isopropyl Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as OCUVEX THERAP. It is marketed under 1 brand name, including OMLONTI. Available in 1 different strength, such as 0.002%, and administered through 1 route including SOLUTION;OPHTHALMIC.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patents

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
✓ Latest exclusivity data and extensions
Unlock Global Access

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

✓ Comprehensive global patent expiry timelines
✓ Full patent family details and status updates
Unlock Global Patent Timeline

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"108658","ingredient":"OMIDENEPAG ISOPROPYL","trade_name":"OMLONTI","family_id":"d63099ccc00c41718d50","publication_number":"US8648097B2","cleaned_patent_number":"8648097","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-10-13","publication_date":"2014-02-11","legal_status":"Granted"} US8648097B2 Molecular Formulation 11 Feb, 2014 Granted 13 Oct, 2029
{"application_id":"108682","ingredient":"OMIDENEPAG ISOPROPYL","trade_name":"OMLONTI","family_id":"8701041f26da493297b2","publication_number":"US8685986B2","cleaned_patent_number":"8685986","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-10-13","publication_date":"2014-04-01","legal_status":"Granted"} US8685986B2 Formulation 01 Apr, 2014 Granted 13 Oct, 2029
{"application_id":"108702","ingredient":"OMIDENEPAG ISOPROPYL","trade_name":"OMLONTI","family_id":"242d82445fcb49af9269","publication_number":"US10765750B2","cleaned_patent_number":"10765750","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-08","publication_date":"2020-09-08","legal_status":"Granted"} US10765750B2 Formulation 08 Sep, 2020 Granted 08 Jan, 2035
{"application_id":"108605","ingredient":"OMIDENEPAG ISOPROPYL","trade_name":"OMLONTI","family_id":"de621760d96048ce9621","publication_number":"US11197849B2","cleaned_patent_number":"11197849","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-08","publication_date":"2021-12-14","legal_status":"Patented case"} US11197849B2 Formulation 14 Dec, 2021 Patented case 08 Jan, 2035
{"application_id":"108644","ingredient":"OMIDENEPAG ISOPROPYL","trade_name":"OMLONTI","family_id":"de621760d96048ce9621","publication_number":"US11793798B2","cleaned_patent_number":"11793798","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-08","publication_date":"2023-10-24","legal_status":"Patented case"} US11793798B2 Formulation 24 Oct, 2023 Patented case 08 Jan, 2035
{"application_id":"108642","ingredient":"OMIDENEPAG ISOPROPYL","trade_name":"OMLONTI","family_id":"de621760d96048ce9621","publication_number":"US10179127B2","cleaned_patent_number":"10179127","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-08","publication_date":"2019-01-15","legal_status":"Granted"} US10179127B2 Formulation 15 Jan, 2019 Granted 08 Jan, 2035
{"application_id":"108643","ingredient":"OMIDENEPAG ISOPROPYL","trade_name":"OMLONTI","family_id":"de621760d96048ce9621","publication_number":"US10702511B2","cleaned_patent_number":"10702511","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-08","publication_date":"2020-07-07","legal_status":"Granted"} US10702511B2 Formulation 07 Jul, 2020 Granted 08 Jan, 2035
{"application_id":"108639","ingredient":"OMIDENEPAG ISOPROPYL","trade_name":"OMLONTI","family_id":"de621760d96048ce9621","publication_number":"US9415038B2","cleaned_patent_number":"9415038","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-08","publication_date":"2016-08-16","legal_status":"Granted"} US9415038B2 Formulation 16 Aug, 2016 Granted 08 Jan, 2035
{"application_id":"108641","ingredient":"OMIDENEPAG ISOPROPYL","trade_name":"OMLONTI","family_id":"de621760d96048ce9621","publication_number":"USRE48183E","cleaned_patent_number":"RE48183","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-01-08","publication_date":"2020-09-01","legal_status":"Granted"} USRE48183E1 Formulation 01 Sep, 2020 Granted 08 Jan, 2035
{"application_id":"108647","ingredient":"OMIDENEPAG ISOPROPYL","trade_name":"OMLONTI","family_id":"ce9ded706ac24cdf98fd","publication_number":"US10774072B2","cleaned_patent_number":"10774072","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-06-10","publication_date":"2020-09-15","legal_status":"Granted"} US10774072B2 Molecular 15 Sep, 2020 Granted 10 Jun, 2035
{"application_id":"115895","ingredient":"OMIDENEPAG ISOPROPYL","trade_name":"OMLONTI","family_id":"e66c45eab63f435181ab","publication_number":"US11666563B2","cleaned_patent_number":"11666563","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2039-07-16","publication_date":"2023-06-06","legal_status":"Granted"} US11666563B2 06 Jun, 2023 Granted 16 Jul, 2039

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Omidenepag Isopropyl

✓ Access a comprehensive list of global suppliers
✓ Get information on each supplier
Unlock Suppliers

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.

GreyB © 2025 Elixir. All rights reserved.